Ftse Mib
33.154,05
-0,10%
DAX
18.235,45
0,17%
S&P 500
5.460,48
-0,41%
NASDAQ
17.732,60
-0,71%
Bitcoin
63.180,38
0,81%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Scinai Immunotherapeutics Ltd (SCNI) Scinai Immunotherapeutics Ltd (SCNI) Notizie

SCNI

Scinai Immunotherapeutics (SCNI)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SCNI
DataOraFonteTitoloSimboloCompagnia
14/06/202413:26Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:SCNIScinai Immunotherapeutics Ltd
13/06/202413:00PR Newswire (US)Scinai Immunotherapeutics Announces Receipt of a Letter of Intent from the European Investment Bank Providing Specific Terms for Conversion of its Loan to Equity.NASDAQ:SCNIScinai Immunotherapeutics Ltd
07/06/202413:00PR Newswire (US)Scinai Immunotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement; Continues to Work with the European Investment Bank to Convert Loan to Equity to Regain Compliance with Nasdaq Minimum Shareholders' Equity RequirementNASDAQ:SCNIScinai Immunotherapeutics Ltd
24/05/202422:01PR Newswire (US)Scinai Immunotherapeutics Announces Receipt of a Nasdaq Staff Determination Letter Regarding Shareholders' Equity listing requirements and Hearing to Present a Plan for Regaining ComplianceNASDAQ:SCNIScinai Immunotherapeutics Ltd
16/05/202419:49Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:SCNIScinai Immunotherapeutics Ltd
15/05/202422:01PR Newswire (US)Scinai Publishes FY 2023 Financial Statements, Files Annual Report on Form 20-F and Provides Business UpdateNASDAQ:SCNIScinai Immunotherapeutics Ltd
06/05/202415:21PR Newswire (US)Scinai Immunotherapeutics Announces Receipt of Nasdaq Delisting Notification and AppealNASDAQ:SCNIScinai Immunotherapeutics Ltd
10/04/202413:00PR Newswire (US)Scinai to showcase its novel biological local therapeutic for Plaque Psoriasis at Dermatology Drug Development Summit together with Prof. Michael Schön of UMGNASDAQ:SCNIScinai Immunotherapeutics Ltd
08/04/202423:15AllPennyStocks.comBiotech Rips Following Five-Year Master Service Agreement ReleaseNASDAQ:SCNIScinai Immunotherapeutics Ltd
08/04/202413:00PR Newswire (US)Scinai Immunotherapeutics' CDMO Unit Selected by Ayana Pharma to Provide Drug Development and cGMP Manufacturing ServicesNASDAQ:SCNIScinai Immunotherapeutics Ltd
12/03/202413:00PR Newswire (US)Scinai leadership to attend BIO-Europe Spring 2024NASDAQ:SCNIScinai Immunotherapeutics Ltd
29/02/202414:45PR Newswire (US)Scinai to showcase its cGMP biologics CDMO and innovative NanoAb pipeline at MIXiii 2024NASDAQ:SCNIScinai Immunotherapeutics Ltd
13/02/202413:00PR Newswire (US)Scinai Welcomes Liat Halpert as Head of Business Development and SalesNASDAQ:SCNIScinai Immunotherapeutics Ltd
30/01/202422:19Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersNASDAQ:SCNIScinai Immunotherapeutics Ltd
25/01/202416:26PR Newswire (US)Scinai Immunotherapeutics Congratulates its Co-Lead Scientific Research Collaborator Dirk Görlich on Louis-Jeantet PrizeNASDAQ:SCNIScinai Immunotherapeutics Ltd
24/01/202420:33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:SCNIScinai Immunotherapeutics Ltd
12/01/202413:32Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:SCNIScinai Immunotherapeutics Ltd
04/01/202422:01PR Newswire (US)Scinai Immunotherapeutics Announces Closing of Exercise of Outstanding Warrants for $1.69 Million in Gross ProceedsNASDAQ:SCNIScinai Immunotherapeutics Ltd
04/01/202412:15PR Newswire (US)Scinai Immunotherapeutics CEO Issues Letter to ShareholdersNASDAQ:SCNIScinai Immunotherapeutics Ltd
29/12/202315:21PR Newswire (US)Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross ProceedsNASDAQ:SCNIScinai Immunotherapeutics Ltd
27/12/202313:15PR Newswire (US)Scinai (NASDAQ: SCNI) to Host Analyst and Investor Webinar on January 9NASDAQ:SCNIScinai Immunotherapeutics Ltd
27/12/202306:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:SCNIScinai Immunotherapeutics Ltd
22/12/202315:11Edgar (US Regulatory)Form F-1/A - Registration statement for certain foreign private issuers: [Amend]NASDAQ:SCNIScinai Immunotherapeutics Ltd
12/12/202313:26PR Newswire (US)Scinai Announces Promising Results in a Psoriatic Human Skin ModelNASDAQ:SCNIScinai Immunotherapeutics Ltd
11/12/202314:11PR Newswire (US)Study published in Antiviral Research supports promise of Scinai Immunotherapeutics' coronavirus NanoAb as aerosolized prophylactic and therapeutic drugNASDAQ:SCNIScinai Immunotherapeutics Ltd
29/11/202315:25PR Newswire (US)European Investment Bank (EIB) extends maturity of its finance facility with Scinai Immunotherapeutics from 2027 to 2031NASDAQ:SCNIScinai Immunotherapeutics Ltd
20/11/202313:30PR Newswire (US)Scinai Immunotherapeutics Regains Compliance with Nasdaq's Stockholders' Equity RuleNASDAQ:SCNIScinai Immunotherapeutics Ltd
06/11/202313:30GlobeNewswire Inc.Scinai Immunotherapeutics Announces Award of Non-Dilutive Grant from Israel Innovation Authority Supporting its New CDMO Business UnitNASDAQ:SCNIScinai Immunotherapeutics Ltd
03/11/202321:30GlobeNewswire Inc.Scinai Immunotherapeutics Provides Update Regarding Nasdaq ComplianceNASDAQ:SCNIScinai Immunotherapeutics Ltd
31/10/202314:00GlobeNewswire Inc.European Investment Bank (EIB) considering extending maturity of its financial facility contract with Scinai Immunotherapeutics in light of Scinai’s recent strategic pivotNASDAQ:SCNIScinai Immunotherapeutics Ltd
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:SCNI

La tua Cronologia

TG
A2GSFX
Volkswagen Financial Ser...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network